Rare Disease · United Kingdom · In-Market

UK Sickle Cell Disease Pricing Strategy Model

NICE recommended crizanlizumab in 2021, then withdrew the guidance in 2023 when the confirmatory trial failed. The licence was revoked. In UK sickle cell, price is not the binding constraint. Confirmatory evidence is.

12-sheet modelManaged access precedentIn-MarketUpdated Q3 2026
Market United States United Kingdom GCC (Gulf) Stage
The Landscape

Both sickle cell therapies NICE has recommended reached patients through managed access, and one lost its licence when the confirmatory data did not hold.

The defining UK sickle cell precedent is a withdrawal, not a rejection. NICE recommended crizanlizumab in October 2021 under technology appraisal TA743, as an option for preventing recurrent vaso-occlusive crises in people aged 16 and over, but only if the conditions of a managed access agreement were met. That agreement existed because the evidence carried real uncertainty and NICE wanted more data before committing to routine commissioning. The data arrived and did not hold. The STAND confirmatory trial failed to show a reduction in crises leading to a healthcare visit, the European Commission revoked the conditional marketing authorisation in August 2023, the MHRA withdrew the UK licence, and NICE withdrew TA743. A drug that had already cleared NICE lost the market on efficacy.

That reframes the pricing question for any new UK sickle cell agent. The constraint is not a published cost-per-QALY ceiling to price beneath. It is that NICE will grant access on uncertain evidence and reclaim it, so the price and the confirmatory evidence plan have to be built as a single decision. Casgevy followed the same conditional route, recommended under TA1044 within a managed access agreement rather than straight to routine commissioning. Our model therefore prices the asset across both managed-access and routine-commissioning scenarios, and weights the revenue case by confirmatory-trial risk instead of assuming one approved price holds for the life of the asset.

2 of 2
sickle cell therapies recommended by NICE that reached patients through a managed access agreement rather than routine commissioning (crizanlizumab TA743; Casgevy TA1044)
TA743
recommended October 2021 under managed access, then withdrawn in 2023 after the marketing authorisation was revoked. This is the precedent every new UK entrant inherits.
Aug 2023
European Commission revoked crizanlizumab's conditional marketing authorisation after the STAND confirmatory trial failed to show a reduction in crises leading to a healthcare visit
£1.65M
Casgevy list price under NICE TA1044, recommended within a managed access agreement and supplied to the NHS at a confidential discount. The only one-time-payment precedent in UK sickle cell.
PRICE LADDER MECHANICS

Every sickle cell therapy NICE has recommended reached patients conditionally, and the conditions have already reclaimed one.

AgentNICE OutcomeAccess RouteWhat Happened Next
Crizanlizumab (Adakveo, Novartis)TA743 recommended, October 2021, ages 16 and overManaged access agreement, conditional on further data collectionLicence revoked 2023 after STAND failed its primary endpoint; NICE withdrew the guidance
Casgevy (exagamglogene autotemcel, Vertex)TA1044 recommendedManaged access agreement; £1.65M list, confidential NHS discountIn managed access, with long-term data collection ongoing
Novel non-gene agentTarget: routine commissioning rather than a conditional routePriced and evidenced to avoid managed access where possibleModelled across both routes, with confirmatory-trial risk weighted into the revenue case

Sources: NICE technology appraisal TA743, crizanlizumab, published October 2021 and subsequently withdrawn following revocation of the marketing authorisation; NICE technology appraisal TA1044, Casgevy, recommended within a managed access agreement; European Medicines Agency and European Commission decisions revoking the Adakveo conditional marketing authorisation, 2023, including the STAND confirmatory-trial result.

Commercial Questions

What this model answers

Every section answers a named commercial question your team is asking, scoped to your asset.

01
Why did crizanlizumab lose the UK market after NICE had already recommended it, and what does that mean for our pricing case?

Delivers

  • The TA743 managed access conditions, the STAND result that triggered revocation, and the confirmatory-trial risk weighting to build into the revenue model
02
Should we target managed access or routine commissioning, and what does each route cost us?

Delivers

  • The two routes NICE has used in UK sickle cell, the evidence commitments each carries, and the price implications of accepting a conditional route
03
What target WAC should a new non-gene SCD agent set, and how does the NHS hospitalisation-offset argument support it?

Delivers

  • The model's target WAC range, per-patient NHS hospitalisation-offset modelling, and the GTN waterfall and PAS negotiation layers specific to the UK sickle cell market

Custom model delivered in 72 hours.

Assess this report
Contents

What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

1 The Binding Constraint 2 pp
  • Why confirmatory-evidence risk, not a cost-per-QALY ceiling, governs UK sickle cell pricing
  • What crizanlizumab's withdrawal changed for every agent that follows it
2 Access Route Ladder — Managed Access vs Routine Commissioning 3 pp
  • The two routes NICE has actually used in sickle cell and what each one demands
  • Where a novel non-gene agent should aim on that ladder
3 One-Time Payment and Amortisation Structures 3 pp
  • How a one-time gene therapy price is absorbed against ongoing NHS management cost
  • Where amortisation and outcome-based structures apply in sickle cell
4 The Crizanlizumab Withdrawal — Anatomy of a Reclaimed Approval 3 pp
  • TA743's managed access conditions and the evidence uncertainty they were built to resolve
  • How the STAND result moved from a trial failure to a revoked licence
5 Value-Based ICER & the Target WAC 3 pp
  • The WAC range the model produces once NHS hospitalisation offsets are built into the case
  • Positioning against hydroxycarbamide's generic cost floor
6 GTN Waterfall & PAS Negotiation Layers 3 pp
  • The WAC-to-net waterfall decomposed by NHS commissioning route
  • Where a confidential PAS discount does and does not change the NICE outcome
7 Launch Sequencing & Revenue Scenarios 4 pp
  • Sequencing recommendation across NHS England specialist centres
  • Conservative, base, and aggressive revenue scenarios tied to NICE submission timing
8 Client Alignment Questions 2 pp
  • The open pricing questions your team must close before the UK launch price is locked
  • Structured for an internal pricing committee session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Formats

Included with every brief

PDF
PDF Brief
Pricing Strategy Brief — Complete Edition
PDF methodology brief accompanying the 12-sheet pricing model: access-route ladder, the crizanlizumab withdrawal precedent, one-time-payment structures, and the GTN waterfall for sickle cell disease UK.
XLS
Excel Model
Pricing Strategy Model — Excel
12-sheet editable model: Price Ladder, PAS Basket, Analogue Benchmarks, Value-Based ICER, GTN Waterfall, Launch Sequencing, Revenue Scenarios, Sensitivity, NICE Landscape, QC, Sources.
Methodology

How AXLRx builds this model

Prepared by MoatRx analysts.

Every AXLRx pricing model is built from primary NICE and NHS sources and live commissioning documentation, not secondary summaries. Findings are independently verified before inclusion.

Sickle cell disease UK pricing sources: NICE TA743 (crizanlizumab, recommended 2021 and later withdrawn), NICE TA1044 (Casgevy), and the European Medicines Agency and European Commission decisions revoking the Adakveo conditional marketing authorisation in 2023.

  • TA743's original recommendation, its managed access conditions, and NICE's subsequent withdrawal verified against the live NICE guidance record, not inferred from the drug's current absence from the UK market
  • Crizanlizumab's licence revocation verified against the European Medicines Agency and European Commission decisions of 2023, including the STAND confirmatory-trial result that triggered them
  • Casgevy's list price and managed access route verified against NICE TA1044
FAQ

Frequently asked questions

Deliverables
What formats are included with every model?
Every commissioned Pricing Strategy Model includes an editable 12-sheet Excel model (Price Ladder, PAS Basket, Analogue Benchmarks, Value-Based ICER, GTN Waterfall, Launch Sequencing, Revenue Scenarios, Sensitivity, NICE Landscape, QC, Sources) and a PDF methodology brief, with no PowerPoint deck, since a pricing model is built to be worked in directly. An optional 45-minute analyst readout call is included.
Sources
How is the pricing evidence verified?
AXLRx builds from primary sources only: NICE technology appraisal documents, NHS England budget modelling, and NHS Hospital Episode Statistics. No secondary summaries or market research reports. Every reference price, mechanism, and timeline input is independently verified before inclusion.
Customisation
Can I model a specific WAC scenario or comparator set?
Yes. The intake form captures your indication, target WAC range, comparator class, and NICE submission timeline. A scoping call confirms scope before research starts. Commission via the intake form to start.
Get Started

Commission this model

AXLRx delivers sickle cell disease pricing strategy models built for market access and pricing teams weighing a managed access route against routine commissioning under NICE. Custom model in 72 hours.

1
Submit your request

Specify your indication, target WAC range, and comparator scope.

2
Scoping call

AXLRx analyst confirms pricing mechanism assumptions and NICE threshold before building.

3
Delivery

Research-verified pricing model in 72 hours with optional analyst readout.